[Federal Register Volume 66, Number 83 (Monday, April 30, 2001)]
[Notices]
[Pages 21406-21407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-10578]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: MHC Class II Restricted 
Melanoma Antigens and Their Use in Therapeutic Methods

<BD>AGENCY: <RM>National Institutes of Health, Public Health Service, 
DHHS.

<BD>ACTION: <RM>Notice

-----------------------------------------------------------------------

<BD>SUMMARY: <RM>This is notice, in accordance with 35 U.S.C. 209(c)(1) 
and 37 CFR 404.7(a)(1)(i), that the National

[[Page 21407]]

Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive license to practice the 
inventions embodied in U.S. Patent Application S/N 08/533,895, filed on 
September 26, 1995, entitled ``MHC Class II Restricted Melanoma 
Antigens and Their Use in Therapeutic Methods'', to Therion Biologics 
Corporation of Cambridge, Massachusetts. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to recombinant poxvirus-based vaccines 
for human cancer immunotherapy, said poxviruses encoding Class II-
restricted melanoma antigens, or modifications, derivatives, or 
immunogenic peptides thereof, and vaccination protocols comprising the 
administration of one or more Class II-restricted melanoma peptides in 
addition to a recombinant poxvirus-based vaccine (for example, in a 
prime and boost protocol), but specifically excluding the use of these 
peptides in any context other than a recombinant poxvirus-based 
vaccination protocol.

<BD>DATES: <RM>Only written comments and/or license applications which 
are received by the National Institutes of Health on or before June 29, 
2001 will be considered.

<BD>ADDRESSES: <RM>Requests for copies of the patent application, 
inquiries, comments and other materials relating to the contemplated 
exclusive license should be directed to: Elaine White, M.B.A., 
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD. 20852-3804. Telephone: (301) 496-7056, X282; Facsimile 
(301) 402-0220; E-mail <a href="/cdn-cgi/l/email-protection#620705565416220c0b0a4c050d14"><span class="__cf_email__" data-cfemail="4a2f2d7e7c3e0a242322642d253c">[email protected]</span></a>.

<BD>SUPPLEMENTARY INFORMATION: <RM>The prospective exclusive license 
will be royalty-bearing and will comply with the terms and conditions 
of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license 
may be granted unless within sixty (60) days from the date of this 
published notice, the NIH receives written evidence and argument that 
establish that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 23, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-10578 Filed 4-27-01; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>